	US 12,186,365 B2
	Composition for regulating cell division comprising FCHO1 modulator, and method for regulating cell division using same
Myung Haing Cho, Seoul (KR); Sung Jin Park, Jangan-gu Gyeonggi-do (KR); Jong Sun Park, Daejeon (KR); and Kwang Pyo Kim, Seoul (KR)
Assigned to Seoul National University R&DB Foundation, Seoul (KR); The IAC in Chungnam National University, Daejeon (KR); and UIC Group of Kyung Hee University, Gyeonggi-do (KR)
Appl. No. 15/776,897
Filed by SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, Seoul (KR)
PCT Filed Nov. 17, 2016, PCT No. PCT/KR2016/013304 § 371(c)(1), (2) Date May 17, 2018, PCT Pub. No. WO2017/086725, PCT Pub. Date May 26, 2017.
Claims priority of application No. 10-2015-0161326 (KR), filed on Nov. 17, 2015; and application No. 10-2016-0153654 (KR), filed on Nov. 17, 2016.
Prior Publication US 2019/0085093 A1, Mar. 21, 2019
Int. Cl. A61K 38/17 (2006.01); A61K 31/713 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 15/113 (2010.01); G01N 33/574 (2006.01)

CPC A61K 38/1709 (2013.01) [A61K 31/713 (2013.01); A61P 35/00 (2018.01); C07K 16/28 (2013.01); C07K 16/3023 (2013.01); C07K 16/3076 (2013.01); C12N 15/113 (2013.01); G01N 33/57484 (2013.01); G01N 33/57492 (2013.01); C12N 2310/14 (2013.01)]

3 Claims

1. A method for treating a cancer, the method comprising administering an FCHo 1 activity inhibitor to a human subject that has cancer,

wherein the FCHo1 inhibitor is selected from the group consisting of:

human FCHo1^S570Aconsisting of SEQ ID NO: 5 with the single mutation S570A, and

human FCho1 del563-564 consisting of SEQ ID NO: 6,

wherein the FCHo1 inhibitor is delivered into target cells by a pharmaceutically acceptable delivery system.